Article

Key clinical point: Bimekizumab led to long-term improvements in efficacy outcomes and had a manageable safety profile in patients with active psoriatic arthritis (PsA) and prior inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

Major finding: At week 16, a significantly higher number of patients achieved ≥50% improvement in American College of Rheumatology response with bimekizumab vs placebo (43.4% vs 6.8%; P < .0001), with improvements sustained up to week 52 by >40% of patients receiving bimekizumab. No new safety signals were observed.

Study details: Findings are from the BE VITAL open-label extension study including 377 patients with active PsA and TNFi-IR who received bimekizumab or placebo for 16 weeks followed by only bimekizumab up to week 52.

Disclosures: This study was sponsored by UCB Pharma. Four authors reported being employees or shareholders of UCB Pharma. Several authors declared receiving research support or consulting fees or having other ties with various sources, including UCB Pharma.

Source: Coates LC, Landewe R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024;10:e003855 (Feb 22). doi: 10.1136/rmdopen-2023-003855 Source

Key clinical point: Bimekizumab led to long-term improvements in efficacy outcomes and had a manageable safety profile in patients with active psoriatic arthritis (PsA) and prior inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

Major finding: At week 16, a significantly higher number of patients achieved ≥50% improvement in American College of Rheumatology response with bimekizumab vs placebo (43.4% vs 6.8%; P < .0001), with improvements sustained up to week 52 by >40% of patients receiving bimekizumab. No new safety signals were observed.

Study details: Findings are from the BE VITAL open-label extension study including 377 patients with active PsA and TNFi-IR who received bimekizumab or placebo for 16 weeks followed by only bimekizumab up to week 52.

Disclosures: This study was sponsored by UCB Pharma. Four authors reported being employees or shareholders of UCB Pharma. Several authors declared receiving research support or consulting fees or having other ties with various sources, including UCB Pharma.

Source: Coates LC, Landewe R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024;10:e003855 (Feb 22). doi: 10.1136/rmdopen-2023-003855 Source

Key clinical point: Bimekizumab led to long-term improvements in efficacy outcomes and had a manageable safety profile in patients with active psoriatic arthritis (PsA) and prior inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

Major finding: At week 16, a significantly higher number of patients achieved ≥50% improvement in American College of Rheumatology response with bimekizumab vs placebo (43.4% vs 6.8%; P < .0001), with improvements sustained up to week 52 by >40% of patients receiving bimekizumab. No new safety signals were observed.

Study details: Findings are from the BE VITAL open-label extension study including 377 patients with active PsA and TNFi-IR who received bimekizumab or placebo for 16 weeks followed by only bimekizumab up to week 52.

Disclosures: This study was sponsored by UCB Pharma. Four authors reported being employees or shareholders of UCB Pharma. Several authors declared receiving research support or consulting fees or having other ties with various sources, including UCB Pharma.

Source: Coates LC, Landewe R, McInnes IB, et al. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL. RMD Open. 2024;10:e003855 (Feb 22). doi: 10.1136/rmdopen-2023-003855 Source

Key clinical point: The incidence rates of major adverse cardiovascular events (MACE) were similar in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA), suggesting that both inflammatory disorders share a common atherogenic mechanism.

Major finding: After a total of 119,571 patient-years of follow-up, 6.7% of patients with RA or PsA developed MACE for the first time. The rates of MACE incidence (adjusted incidence rate ratio 0.96; P  =  .767) and MACE-free survival (P  =  .987) were comparable between patients with PsA and RA. Higher time-varying erythrocyte sedimentation rate, C-reactive protein levels, and exposure to glucocorticoids increased the risk for MACE in both patients with PsA and RA (all P < .05).

Study details: This population based retrospective cohort study included 13,905 patients with PsA (n  =  1672) or RA (n  =  12,233) who did not have any previous history of MACE.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Meng H, Lam SH, So H, Tam LS. Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study. Semin Arthritis Rheum. 2024;65:152416 (Feb 17). Source

Key clinical point: The incidence rates of major adverse cardiovascular events (MACE) were similar in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA), suggesting that both inflammatory disorders share a common atherogenic mechanism.

Major finding: After a total of 119,571 patient-years of follow-up, 6.7% of patients with RA or PsA developed MACE for the first time. The rates of MACE incidence (adjusted incidence rate ratio 0.96; P  =  .767) and MACE-free survival (P  =  .987) were comparable between patients with PsA and RA. Higher time-varying erythrocyte sedimentation rate, C-reactive protein levels, and exposure to glucocorticoids increased the risk for MACE in both patients with PsA and RA (all P < .05).

Study details: This population based retrospective cohort study included 13,905 patients with PsA (n  =  1672) or RA (n  =  12,233) who did not have any previous history of MACE.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Meng H, Lam SH, So H, Tam LS. Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study. Semin Arthritis Rheum. 2024;65:152416 (Feb 17). Source

Key clinical point: The incidence rates of major adverse cardiovascular events (MACE) were similar in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA), suggesting that both inflammatory disorders share a common atherogenic mechanism.

Major finding: After a total of 119,571 patient-years of follow-up, 6.7% of patients with RA or PsA developed MACE for the first time. The rates of MACE incidence (adjusted incidence rate ratio 0.96; P  =  .767) and MACE-free survival (P  =  .987) were comparable between patients with PsA and RA. Higher time-varying erythrocyte sedimentation rate, C-reactive protein levels, and exposure to glucocorticoids increased the risk for MACE in both patients with PsA and RA (all P < .05).

Study details: This population based retrospective cohort study included 13,905 patients with PsA (n  =  1672) or RA (n  =  12,233) who did not have any previous history of MACE.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Meng H, Lam SH, So H, Tam LS. Incidence and risk factors of major cardiovascular events in rheumatoid arthritis and psoriatic arthritis: A population-based cohort study. Semin Arthritis Rheum. 2024;65:152416 (Feb 17). Source

Key clinical point: Ixekizumab was more effective than adalimumab in resolving distal interphalangeal (DIP) joint tenderness, swelling, and adjacent nail psoriasis in patients with psoriatic arthritis (PsA) and DIP joint involvement who nearly invariably had adjacent nail psoriasis.

Major finding: More than 96% of patients with PsA and simultaneous DIP joint involvement reported adjacent nail psoriasis in at least one digit in the finger unit. Ixekizumab vs adalimumab led to greater improvements in DIP involvement and adjacent nail psoriasis as early as week 12 (38.8% vs 28.4%; P < .0001), with improvements sustained up to week 52 (64.9% vs 57.5%; P  =  .0055).

Study details: This post hoc analysis of the SPIRIT-H2H study included 354 patients with PsA who had simultaneous DIP joint involvement and adjacent nail psoriasis and were randomly assigned to receive ixekizumab or adalimumab.

Disclosures: This study was supported by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly and Company. The other authors reported ties with various sources, including Eli Lilly and Company.

Source: McGonagle D, Kavanaugh A, McInnes IB, et al. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology (Oxford). 2024 (Feb 10). doi: 10.1093/rheumatology/keae060 Source

Key clinical point: Ixekizumab was more effective than adalimumab in resolving distal interphalangeal (DIP) joint tenderness, swelling, and adjacent nail psoriasis in patients with psoriatic arthritis (PsA) and DIP joint involvement who nearly invariably had adjacent nail psoriasis.

Major finding: More than 96% of patients with PsA and simultaneous DIP joint involvement reported adjacent nail psoriasis in at least one digit in the finger unit. Ixekizumab vs adalimumab led to greater improvements in DIP involvement and adjacent nail psoriasis as early as week 12 (38.8% vs 28.4%; P < .0001), with improvements sustained up to week 52 (64.9% vs 57.5%; P  =  .0055).

Study details: This post hoc analysis of the SPIRIT-H2H study included 354 patients with PsA who had simultaneous DIP joint involvement and adjacent nail psoriasis and were randomly assigned to receive ixekizumab or adalimumab.

Disclosures: This study was supported by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly and Company. The other authors reported ties with various sources, including Eli Lilly and Company.

Source: McGonagle D, Kavanaugh A, McInnes IB, et al. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology (Oxford). 2024 (Feb 10). doi: 10.1093/rheumatology/keae060 Source

Key clinical point: Ixekizumab was more effective than adalimumab in resolving distal interphalangeal (DIP) joint tenderness, swelling, and adjacent nail psoriasis in patients with psoriatic arthritis (PsA) and DIP joint involvement who nearly invariably had adjacent nail psoriasis.

Major finding: More than 96% of patients with PsA and simultaneous DIP joint involvement reported adjacent nail psoriasis in at least one digit in the finger unit. Ixekizumab vs adalimumab led to greater improvements in DIP involvement and adjacent nail psoriasis as early as week 12 (38.8% vs 28.4%; P < .0001), with improvements sustained up to week 52 (64.9% vs 57.5%; P  =  .0055).

Study details: This post hoc analysis of the SPIRIT-H2H study included 354 patients with PsA who had simultaneous DIP joint involvement and adjacent nail psoriasis and were randomly assigned to receive ixekizumab or adalimumab.

Disclosures: This study was supported by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly and Company. The other authors reported ties with various sources, including Eli Lilly and Company.

Source: McGonagle D, Kavanaugh A, McInnes IB, et al. Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis. Rheumatology (Oxford). 2024 (Feb 10). doi: 10.1093/rheumatology/keae060 Source

Key clinical point: The risk factors for overall breast cancer (such as parity, menopausal hormone therapy use, and alcohol consumption) did not increase the risk for triple-negative breast cancer (TNBC), which had a distinct risk factor profile.

Major finding: Parity, menopausal hormone therapy use, alcohol consumption, smoking, and higher body mass index were not significantly associated with TNBC risk (all P > .05); instead, family history (odds ratio [OR] 1.55; P < .001), longer duration of oral contraceptive use (OR 1.29; P < .001), and higher breast density (OR 2.19; P < .001) were significantly associated with an increased risk for TNBC.

Study details: This meta-analysis evaluated the association between TNBC incidence and established BC risk factors using data from 33 studies.

Disclosures: This study was supported by grants from the American Cancer Society and Royal College of Surgeons in Ireland - Medical University of Bahrain (RCSI-MUB Bahrain). The authors declared no conflicts of interest.

Source: Kumar N, Ehsan S, Banerjee S, et al. The unique risk factor profile of triple negative breast cancer: A comprehensive meta-analysis. J Natl Cancer Inst. 2024 (Mar 5). Doi: 10.1093/jnci/djae056 Source

Key clinical point: The risk factors for overall breast cancer (such as parity, menopausal hormone therapy use, and alcohol consumption) did not increase the risk for triple-negative breast cancer (TNBC), which had a distinct risk factor profile.

Major finding: Parity, menopausal hormone therapy use, alcohol consumption, smoking, and higher body mass index were not significantly associated with TNBC risk (all P > .05); instead, family history (odds ratio [OR] 1.55; P < .001), longer duration of oral contraceptive use (OR 1.29; P < .001), and higher breast density (OR 2.19; P < .001) were significantly associated with an increased risk for TNBC.

Study details: This meta-analysis evaluated the association between TNBC incidence and established BC risk factors using data from 33 studies.

Disclosures: This study was supported by grants from the American Cancer Society and Royal College of Surgeons in Ireland - Medical University of Bahrain (RCSI-MUB Bahrain). The authors declared no conflicts of interest.

Source: Kumar N, Ehsan S, Banerjee S, et al. The unique risk factor profile of triple negative breast cancer: A comprehensive meta-analysis. J Natl Cancer Inst. 2024 (Mar 5). Doi: 10.1093/jnci/djae056 Source

Key clinical point: The risk factors for overall breast cancer (such as parity, menopausal hormone therapy use, and alcohol consumption) did not increase the risk for triple-negative breast cancer (TNBC), which had a distinct risk factor profile.

Major finding: Parity, menopausal hormone therapy use, alcohol consumption, smoking, and higher body mass index were not significantly associated with TNBC risk (all P > .05); instead, family history (odds ratio [OR] 1.55; P < .001), longer duration of oral contraceptive use (OR 1.29; P < .001), and higher breast density (OR 2.19; P < .001) were significantly associated with an increased risk for TNBC.

Study details: This meta-analysis evaluated the association between TNBC incidence and established BC risk factors using data from 33 studies.

Disclosures: This study was supported by grants from the American Cancer Society and Royal College of Surgeons in Ireland - Medical University of Bahrain (RCSI-MUB Bahrain). The authors declared no conflicts of interest.

Source: Kumar N, Ehsan S, Banerjee S, et al. The unique risk factor profile of triple negative breast cancer: A comprehensive meta-analysis. J Natl Cancer Inst. 2024 (Mar 5). Doi: 10.1093/jnci/djae056 Source

Key clinical point: The pro-vegetarian dietary pattern (PDP) was associated with a significantly lower risk for breast cancer (BC) in women, particularly postmenopausal women.

Major finding: Compared with women who had low adherence to PDP (score ≤ 33), the risk for BC was significantly lower among women with moderate adherence to PDP (score 34-38; adjusted odds ratio [aOR] 0.42; P = .003) and in those with high adherence to PDP (score ≥ 39; aOR 0.49; P = .017), with outcomes being similar in the subgroup of postmenopausal women.

Study details: Findings are from a case-control study including women with BC (n = 134) and those without cancer (n = 265).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Hosseini Y, Hadi Sichani P, Moslemi E, et al. Pro-vegetarian dietary pattern and risk of breast cancer: A case-control study. Breast Cancer Res Treat. 2024 (Feb 28). doi: 10.1007/s10549-024-07243-8 Source

Key clinical point: The pro-vegetarian dietary pattern (PDP) was associated with a significantly lower risk for breast cancer (BC) in women, particularly postmenopausal women.

Major finding: Compared with women who had low adherence to PDP (score ≤ 33), the risk for BC was significantly lower among women with moderate adherence to PDP (score 34-38; adjusted odds ratio [aOR] 0.42; P = .003) and in those with high adherence to PDP (score ≥ 39; aOR 0.49; P = .017), with outcomes being similar in the subgroup of postmenopausal women.

Study details: Findings are from a case-control study including women with BC (n = 134) and those without cancer (n = 265).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Hosseini Y, Hadi Sichani P, Moslemi E, et al. Pro-vegetarian dietary pattern and risk of breast cancer: A case-control study. Breast Cancer Res Treat. 2024 (Feb 28). doi: 10.1007/s10549-024-07243-8 Source

Key clinical point: The pro-vegetarian dietary pattern (PDP) was associated with a significantly lower risk for breast cancer (BC) in women, particularly postmenopausal women.

Major finding: Compared with women who had low adherence to PDP (score ≤ 33), the risk for BC was significantly lower among women with moderate adherence to PDP (score 34-38; adjusted odds ratio [aOR] 0.42; P = .003) and in those with high adherence to PDP (score ≥ 39; aOR 0.49; P = .017), with outcomes being similar in the subgroup of postmenopausal women.

Study details: Findings are from a case-control study including women with BC (n = 134) and those without cancer (n = 265).

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Hosseini Y, Hadi Sichani P, Moslemi E, et al. Pro-vegetarian dietary pattern and risk of breast cancer: A case-control study. Breast Cancer Res Treat. 2024 (Feb 28). doi: 10.1007/s10549-024-07243-8 Source

Key clinical point: Everolimus + exemestane demonstrated good efficacy and had a manageable safety profile in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC).

Major finding: Everolimus + exemestane led to a median progression-free survival (PFS) of 6.6 months (95% CI 6.3-7.0 months). PFS was more favorable among patients with a greater vs lower body mass index (≥25 vs 20 to <25 kg/m²; P < .0001); however, the survival outcomes were worse among patients with vs without visceral metastases (hazard ratio 1.417; P < .0001). Stomatitis (42.6%) and fatigue (19.8%) were the most frequent adverse events.

Study details: Findings are from a prospective, non-interventional study including 2074 postmenopausal women with HR+/HER2− advanced BC who received everolimus + exemestane.

Disclosures: This study was funded by Novartis Deutschland GmbH, Germany. Two authors declared being employees of or holding stocks in Novartis. Some authors declared receiving honoraria or personal fees or having other ties with Novartis and various other sources. Eight authors declared no conflicts of interest.

Source: Lüftner D, Schuetz F, Schneeweiss A, et al. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. Int J Cancer. 2024 (Mar 6). doi: 10.1002/ijc.34912 Source

Key clinical point: Everolimus + exemestane demonstrated good efficacy and had a manageable safety profile in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC).

Major finding: Everolimus + exemestane led to a median progression-free survival (PFS) of 6.6 months (95% CI 6.3-7.0 months). PFS was more favorable among patients with a greater vs lower body mass index (≥25 vs 20 to <25 kg/m²; P < .0001); however, the survival outcomes were worse among patients with vs without visceral metastases (hazard ratio 1.417; P < .0001). Stomatitis (42.6%) and fatigue (19.8%) were the most frequent adverse events.

Study details: Findings are from a prospective, non-interventional study including 2074 postmenopausal women with HR+/HER2− advanced BC who received everolimus + exemestane.

Disclosures: This study was funded by Novartis Deutschland GmbH, Germany. Two authors declared being employees of or holding stocks in Novartis. Some authors declared receiving honoraria or personal fees or having other ties with Novartis and various other sources. Eight authors declared no conflicts of interest.

Source: Lüftner D, Schuetz F, Schneeweiss A, et al. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. Int J Cancer. 2024 (Mar 6). doi: 10.1002/ijc.34912 Source

Key clinical point: Everolimus + exemestane demonstrated good efficacy and had a manageable safety profile in postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC).

Major finding: Everolimus + exemestane led to a median progression-free survival (PFS) of 6.6 months (95% CI 6.3-7.0 months). PFS was more favorable among patients with a greater vs lower body mass index (≥25 vs 20 to <25 kg/m²; P < .0001); however, the survival outcomes were worse among patients with vs without visceral metastases (hazard ratio 1.417; P < .0001). Stomatitis (42.6%) and fatigue (19.8%) were the most frequent adverse events.

Study details: Findings are from a prospective, non-interventional study including 2074 postmenopausal women with HR+/HER2− advanced BC who received everolimus + exemestane.

Disclosures: This study was funded by Novartis Deutschland GmbH, Germany. Two authors declared being employees of or holding stocks in Novartis. Some authors declared receiving honoraria or personal fees or having other ties with Novartis and various other sources. Eight authors declared no conflicts of interest.

Source: Lüftner D, Schuetz F, Schneeweiss A, et al. Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study. Int J Cancer. 2024 (Mar 6). doi: 10.1002/ijc.34912 Source

Key clinical point: Sentinel lymph node biopsy (SLNB), a less invasive strategy, resulted in comparable survival and regional disease control as axillary lymph node dissection (ALND) in patients with sentinel node-positive early breast cancer (BC) who underwent total mastectomy (TM).

Major finding: There were no significant differences in 5-year ipsilateral locoregional recurrence-free survival (LRRFS; P = .21), 5-year distant metastasis-free survival (P = .96), and disease-free survival (P > .05) between the SLNB-alone and ALND groups. However, receipt vs no receipt of radiation therapy improved local disease control in the SLNB group (5-year LRRFS; 100.0% vs 92.9%; P = .02).

Study details: Findings are from a retrospective study including 643 patients with early BC with 1-3 metastatic sentinel lymph nodes who underwent total mastectomy, of which 237 and 406 patients underwent SLNB alone and completion ALND, respectively.

Disclosures: The open access funding for this study was enabled and organized by Seoul National University. The authors declared no conflicts of interest.

Source: Chun JW, Kang E, Kim H-K, et al. Oncological safety of skipping axillary lymph node dissection in patients with clinical N0, sentinel node-positive breast cancer undergoing total mastectomy. Ann Surg Oncol. 2024 (Feb 17). doi: 10.1245/s10434-024-15049-7 Source

Key clinical point: Sentinel lymph node biopsy (SLNB), a less invasive strategy, resulted in comparable survival and regional disease control as axillary lymph node dissection (ALND) in patients with sentinel node-positive early breast cancer (BC) who underwent total mastectomy (TM).

Major finding: There were no significant differences in 5-year ipsilateral locoregional recurrence-free survival (LRRFS; P = .21), 5-year distant metastasis-free survival (P = .96), and disease-free survival (P > .05) between the SLNB-alone and ALND groups. However, receipt vs no receipt of radiation therapy improved local disease control in the SLNB group (5-year LRRFS; 100.0% vs 92.9%; P = .02).

Study details: Findings are from a retrospective study including 643 patients with early BC with 1-3 metastatic sentinel lymph nodes who underwent total mastectomy, of which 237 and 406 patients underwent SLNB alone and completion ALND, respectively.

Disclosures: The open access funding for this study was enabled and organized by Seoul National University. The authors declared no conflicts of interest.

Source: Chun JW, Kang E, Kim H-K, et al. Oncological safety of skipping axillary lymph node dissection in patients with clinical N0, sentinel node-positive breast cancer undergoing total mastectomy. Ann Surg Oncol. 2024 (Feb 17). doi: 10.1245/s10434-024-15049-7 Source

Key clinical point: Sentinel lymph node biopsy (SLNB), a less invasive strategy, resulted in comparable survival and regional disease control as axillary lymph node dissection (ALND) in patients with sentinel node-positive early breast cancer (BC) who underwent total mastectomy (TM).

Major finding: There were no significant differences in 5-year ipsilateral locoregional recurrence-free survival (LRRFS; P = .21), 5-year distant metastasis-free survival (P = .96), and disease-free survival (P > .05) between the SLNB-alone and ALND groups. However, receipt vs no receipt of radiation therapy improved local disease control in the SLNB group (5-year LRRFS; 100.0% vs 92.9%; P = .02).

Study details: Findings are from a retrospective study including 643 patients with early BC with 1-3 metastatic sentinel lymph nodes who underwent total mastectomy, of which 237 and 406 patients underwent SLNB alone and completion ALND, respectively.

Disclosures: The open access funding for this study was enabled and organized by Seoul National University. The authors declared no conflicts of interest.

Source: Chun JW, Kang E, Kim H-K, et al. Oncological safety of skipping axillary lymph node dissection in patients with clinical N0, sentinel node-positive breast cancer undergoing total mastectomy. Ann Surg Oncol. 2024 (Feb 17). doi: 10.1245/s10434-024-15049-7 Source

Key clinical point: The coexistence of obesity and family history of cancer significantly increased the risk for breast cancer (BC) in women, suggesting that weight management is important in women with a family history of cancer.

Major finding: The risk for BC was significantly higher in women with vs without a family history of BC (adjusted hazard ratio [aHR] 1.63; 95% CI 1.22-2.49). The risk was further elevated in women with a body mass index (BMI) ≥ 24 kg/m² and a family history of cancer vs women with BMI < 24 kg/m² and no family history of cancer (adjusted hazard ratio 2.06; 95% CI 1.39-3.06).

Study details: Findings are from a population-based prospective cohort study that included 15,055 women, of which 4210 women had a family history of cancer.

Disclosures: This study was supported by the Nature Science Foundation of Minhang district, Shanghai, China. The authors declared no conflicts of interest.

Source: Cao J, Li J, Zhang Z, et al. Interaction between body mass index and family history of cancer on the risk of female breast cancer. Sci Rep. 2024;14:4927 (Feb 28). doi: 10.1038/s41598-024-54762-x Source

Key clinical point: The coexistence of obesity and family history of cancer significantly increased the risk for breast cancer (BC) in women, suggesting that weight management is important in women with a family history of cancer.

Major finding: The risk for BC was significantly higher in women with vs without a family history of BC (adjusted hazard ratio [aHR] 1.63; 95% CI 1.22-2.49). The risk was further elevated in women with a body mass index (BMI) ≥ 24 kg/m² and a family history of cancer vs women with BMI < 24 kg/m² and no family history of cancer (adjusted hazard ratio 2.06; 95% CI 1.39-3.06).

Study details: Findings are from a population-based prospective cohort study that included 15,055 women, of which 4210 women had a family history of cancer.

Disclosures: This study was supported by the Nature Science Foundation of Minhang district, Shanghai, China. The authors declared no conflicts of interest.

Source: Cao J, Li J, Zhang Z, et al. Interaction between body mass index and family history of cancer on the risk of female breast cancer. Sci Rep. 2024;14:4927 (Feb 28). doi: 10.1038/s41598-024-54762-x Source

Key clinical point: The coexistence of obesity and family history of cancer significantly increased the risk for breast cancer (BC) in women, suggesting that weight management is important in women with a family history of cancer.

Major finding: The risk for BC was significantly higher in women with vs without a family history of BC (adjusted hazard ratio [aHR] 1.63; 95% CI 1.22-2.49). The risk was further elevated in women with a body mass index (BMI) ≥ 24 kg/m² and a family history of cancer vs women with BMI < 24 kg/m² and no family history of cancer (adjusted hazard ratio 2.06; 95% CI 1.39-3.06).

Study details: Findings are from a population-based prospective cohort study that included 15,055 women, of which 4210 women had a family history of cancer.

Disclosures: This study was supported by the Nature Science Foundation of Minhang district, Shanghai, China. The authors declared no conflicts of interest.

Source: Cao J, Li J, Zhang Z, et al. Interaction between body mass index and family history of cancer on the risk of female breast cancer. Sci Rep. 2024;14:4927 (Feb 28). doi: 10.1038/s41598-024-54762-x Source

Key clinical point: Compared with mastectomy, breast-conserving surgery (BCS) led to comparable locoregional recurrence (LRR; the first relapse site) events along with improved survival outcomes in patients with early-stage node-negative triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.

Major finding: BCS vs mastectomy following neoadjuvant chemotherapy did not increase LRR (P = .5209) and was significantly associated with improved disease-free survival (adjusted hazard ratio [aHR] 0.51; P < .001) and overall survival (aHR 0.43; P < .001). Absence of pathologic complete response was the only determinant for worsened LRR risk (HR 2.22; P = .001).

Study details: This retrospective analysis of eight prospective trials included 1074 neoadjuvant chemotherapy-treated patients with early-stage node-negative TNBC and available surgery data.

Disclosures: This study received financial support from Deutschen Forschungsgemeinschaft (DFG) within the funding program Open Access Publikationskosten. Three authors declared being employees of GBG Forschungs GmbH. Ninel authors declared receiving honoraria, grants, consulting fees, or personal fees or having other ties with various sources. The other authors had no conflicts to declare.

Source: Krug D, Vladimirova V, Untch M, et al. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast. 2024;74:103701 (Feb 24). doi: 10.1016/j.breast.2024.103701 Source

Key clinical point: Compared with mastectomy, breast-conserving surgery (BCS) led to comparable locoregional recurrence (LRR; the first relapse site) events along with improved survival outcomes in patients with early-stage node-negative triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.

Major finding: BCS vs mastectomy following neoadjuvant chemotherapy did not increase LRR (P = .5209) and was significantly associated with improved disease-free survival (adjusted hazard ratio [aHR] 0.51; P < .001) and overall survival (aHR 0.43; P < .001). Absence of pathologic complete response was the only determinant for worsened LRR risk (HR 2.22; P = .001).

Study details: This retrospective analysis of eight prospective trials included 1074 neoadjuvant chemotherapy-treated patients with early-stage node-negative TNBC and available surgery data.

Disclosures: This study received financial support from Deutschen Forschungsgemeinschaft (DFG) within the funding program Open Access Publikationskosten. Three authors declared being employees of GBG Forschungs GmbH. Ninel authors declared receiving honoraria, grants, consulting fees, or personal fees or having other ties with various sources. The other authors had no conflicts to declare.

Source: Krug D, Vladimirova V, Untch M, et al. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast. 2024;74:103701 (Feb 24). doi: 10.1016/j.breast.2024.103701 Source

Key clinical point: Compared with mastectomy, breast-conserving surgery (BCS) led to comparable locoregional recurrence (LRR; the first relapse site) events along with improved survival outcomes in patients with early-stage node-negative triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.

Major finding: BCS vs mastectomy following neoadjuvant chemotherapy did not increase LRR (P = .5209) and was significantly associated with improved disease-free survival (adjusted hazard ratio [aHR] 0.51; P < .001) and overall survival (aHR 0.43; P < .001). Absence of pathologic complete response was the only determinant for worsened LRR risk (HR 2.22; P = .001).

Study details: This retrospective analysis of eight prospective trials included 1074 neoadjuvant chemotherapy-treated patients with early-stage node-negative TNBC and available surgery data.

Disclosures: This study received financial support from Deutschen Forschungsgemeinschaft (DFG) within the funding program Open Access Publikationskosten. Three authors declared being employees of GBG Forschungs GmbH. Ninel authors declared receiving honoraria, grants, consulting fees, or personal fees or having other ties with various sources. The other authors had no conflicts to declare.

Source: Krug D, Vladimirova V, Untch M, et al. Breast-conserving surgery is not associated with increased local recurrence in patients with early-stage node-negative triple-negative breast cancer treated with neoadjuvant chemotherapy. Breast. 2024;74:103701 (Feb 24). doi: 10.1016/j.breast.2024.103701 Source

Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.

Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m² (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m² increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).

Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.

Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.

Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source

Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.

Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m² (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m² increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).

Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.

Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.

Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source

Key clinical point: The risk for breast cancer (BC) was significantly elevated in female 5-year survivors of Hodgkin lymphoma (HL) who were treated with doxorubicin between the ages of 15 and 50 years.

Major finding: The risk for BC was 1.4 times higher (95% CI 1.04-1.9) in survivors of HL who did vs did not receive doxorubicin, with the risk increasing further in survivors who received a cumulative doxorubicin dose > 200 mg/m² (adjusted hazard ratio 1.5; 95% CI 1.08-2.1). In fact, every 100 mg/m² increase in doxorubicin dose increased the risk for BC by 1.18 times (95% CI 1.05-1.32).

Study details: Findings are from a cohort study including 5-year survivors of HL (n = 1964) who received treatment between the ages of 15 and 50 years, of whom 1113 patients received doxorubicin.

Disclosures: This study was supported by grants from the Dutch Cancer Society, Netherlands. Five authors declared receiving honoraria, research funding, travel, accommodations, or other expenses from or serving in consulting or advisory roles or as speakers' bureau members for various sources.

Source: Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Doxorubicin exposure and breast cancer risk in survivors of adolescent and adult Hodgkin lymphoma. J Clin Oncol. 2024 (Feb 15). doi: 10.1200/JCO.23.01386 Source